106 related articles for article (PubMed ID: 35395983)
1. [The Relationship between Hematopoietic Scoring System Composed of HB，PLT and MCV and Prognosis and Curative Effect of Multiple Myeloma Patients].
Song LM; Ma YP; Xue R; Cheng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):481-486. PubMed ID: 35395983
[TBL] [Abstract][Full Text] [Related]
2. [The effect of peripheral blood cell score on the prognosis of multiple myeloma patients treated with bortezomib].
Qiu L; Han XY; He DH; Zhu F; Zhao Y; Zhu WW; Zheng GF; Yang Y; Wu WW; Cai Z; Yang XC; He JS
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):756-761. PubMed ID: 33113608
[No Abstract] [Full Text] [Related]
3. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients.
Al Saleh AS; Sidiqi MH; Dispenzieri A; Kapoor P; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2020 Jan; 95(1):4-9. PubMed ID: 31612526
[TBL] [Abstract][Full Text] [Related]
4. [The Influence of CONUT Score on the Prognosis of Patients with Multiple Myeloma].
Li YQ; Wang Y; Song Y; Han Y; Li JJ; Yue LL; Zeng PY; Wu CY; Chai Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):781-786. PubMed ID: 34105472
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era.
Liu S; Shi J; Guo H; Xu F; Wei M; Sun K; Chen Y
Cancer Manag Res; 2019; 11():9409-9420. PubMed ID: 31807070
[TBL] [Abstract][Full Text] [Related]
6. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
7. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
9. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
10. [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].
Shi ZX; Qin TJ; Xu ZF; Huang HJ; Li B; Qu SQ; Hu NB; Pan LJ; Liu D; Cai YN; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):28-33. PubMed ID: 32023751
[No Abstract] [Full Text] [Related]
11. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis.
Liu WN; Chang CF; Chung CH; Chien WC; Huang TC; Wu YY; Ho CL; Chen JH
PLoS One; 2019; 14(9):e0222522. PubMed ID: 31527921
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of IgG Levels at Initial Diagnosis with Clinical Efficacy and Prognosis in 66 Patients with IgG Multiple Myeloma].
Nian FG; Li F; Shao LJ; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1159-1165. PubMed ID: 31418373
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
14. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
[No Abstract] [Full Text] [Related]
15. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
Liu Y; Ke XY; Wang J; Jing HM; Wang JJ; Dong F; Wan WL; Zhang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1628-32. PubMed ID: 25543487
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis].
Shi J; Zhu ZM; Sun K; Lei PC; Liu ZW; Guo JM; Yang J; Zang YZ; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):744-749. PubMed ID: 31648475
[No Abstract] [Full Text] [Related]
18. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
[TBL] [Abstract][Full Text] [Related]
20. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients.
Zhang F; Chen Z; Wang P; Hu X; Gao Y; He J
Tumour Biol; 2016 Jul; 37(7):9323-31. PubMed ID: 26779631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
